« Tamoxifen following chemotherapy improves breast cancer outcome | Home | Caregivers of Bipolar Disorder patients show ill health and depression »
Research confirms benefit of intensive approach to lipid-lowering.
By jeremyc | December 14, 2009
MedPage Today (12/11, Peck) reported that “post-hoc analyses of two landmark statin trials — PROVE-IT and IDEAL — affirm the value of an intensive versus moderate approach to lipid-lowering.” In fact, “staying the course with intensive lipid-lowering — in this case 80 mg atorvastatin (Lipitor) versus either 40 mg pravastatin (Pravachol) or 20-40 mg of simvastatin (Zocor) — actually ‘reduces events by about 50% over time,’ Christopher Cannon, MD,” said. MedPage Today added, “This is ‘an even more dramatic reduction in events’ than the benefit seen at the primary endpoint of 30 days, Cannon said during a discussion of findings from both post-hoc analyses at an American College of Cardiology press conference.”
Topics: | Cholesterol, Statins |
Comments are closed.
